-+ 0.00%
-+ 0.00%
-+ 0.00%

Keros Therapeutics Presents Additional Data From Its Phase 1 Clinical Study Of Rinvatercept In Health Volunteers At 2026 Muscular Dystrophy Association Clinical & Scientific Conference

Benzinga·03/09/2026 12:10:28
Listen to the news

Keros Therapeutics, Inc. ("Keros" or the "Company") (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta ("TGF-ß") family of proteins, today announced that it presented additional data from its Phase 1 clinical trial of rinvatercept (KER-065) in healthy volunteers at the 2026 Muscular Dystrophy Association Clinical & Scientific Conference.

"We are pleased to present additional data that further underscore the wide-ranging therapeutic potential of rinvatercept," said Jasbir S. Seehra, President and Chief Executive Officer of Keros. "These data continue to reinforce the potential of rinvatercept to treat neuromuscular diseases, and our focus remains on advancing the rinvatercept program into two Phase 2 clinical trials, one in Duchenne muscular dystrophy ("DMD") and one in amyotrophic lateral sclerosis ("ALS")."